MedicalRegulation – Stem Cell Therapy for Autism Declared Illegal by NMC Advisory

MedicalRegulation –  The National Medical Commission (NMC) has formally barred the use of stem cell therapy for treating Autism Spectrum Disorder, issuing a fresh advisory that aligns with a recent Supreme Court ruling. The directive aims to address growing concerns over unverified medical claims and unauthorized treatments being offered across the country.

Clear Ban on Unapproved Autism Treatments

In its communication dated March 25, the NMC instructed all medical colleges, hospitals, and registered practitioners to strictly avoid using stem cell therapy for autism and similar neurological conditions unless explicitly approved. The advisory comes in response to increasing reports of private clinics, especially in metro and tier-2 cities, promoting such therapies without scientific validation.

Officials indicated that these practices not only lack regulatory approval but also risk misleading patients and families seeking treatment options for complex developmental disorders.

Limited Approval for Specific Diseases

The NMC clarified that stem cell therapy remains permitted only for a defined list of 32 medical conditions. These include serious illnesses such as Acute Myeloid Leukemia, Multiple Sclerosis, Thalassemia, and Aplastic Anaemia, among others.

This list has been prepared based on recommendations from the Indian Council of Medical Research (ICMR), which evaluated scientific evidence and clinical outcomes before identifying approved uses. Any application of stem cell therapy beyond these conditions will now be treated as a violation of medical regulations.

Supreme Court Judgment Shapes Policy

The advisory follows a significant judgment delivered by the Supreme Court earlier this year regarding the use of stem cell therapy for Autism Spectrum Disorder. The court emphasized the need for strict oversight and adherence to evidence-based practices in medical treatments.

Subsequently, ICMR Director General Dr. Rajiv Bahl communicated with NMC leadership, outlining the approved indications and reinforcing that any deviation from these guidelines would be considered unlawful.

Strict Regulatory Framework Introduced

According to the new guidelines, stem cell therapy can only be administered as part of standard care for approved conditions. For all other uses, it is permitted solely within the framework of controlled research.

Such research must receive prior approval from relevant authorities, including the Central Drugs Standard Control Organisation (CDSCO) or the Department of Health Research (DHR), depending on how the stem cells are processed. Trials must also be cleared by institutional ethics committees and the National Stem Cell Research Regulation Committee.

The advisory further specifies that the level of manipulation of stem cells determines the regulatory pathway, with detailed classifications already defined by CDSCO guidelines.

Ethical Safeguards for Clinical Research

For research-based applications, the NMC has emphasized strict adherence to ethical standards. Patients must provide informed consent in writing, and no financial burden should be placed on them for participating in clinical trials. Additionally, provisions for compensation in case of injury or adverse outcomes are mandatory.

These measures are intended to ensure patient safety while maintaining transparency and accountability in experimental treatments.

Legal Action for Non-Compliance

The advisory clearly states that any use of stem cell therapy outside approved indications, or without authorization from CDSCO or DHR, will be treated as illegal. Medical practitioners and institutions violating these rules may face regulatory penalties and legal consequences.

Authorities believe that this step will help eliminate misleading treatment claims and protect patients from unproven medical interventions.

Focus on Evidence-Based Healthcare

With this move, the NMC aims to reinforce the importance of scientifically validated treatments in India’s healthcare system. By restricting stem cell therapy to approved uses and regulated research, the commission seeks to ensure patient safety while encouraging responsible medical innovation.